D609

D609, an antitumoural xanthate, is a specific and competitive phosphatidyl choline-specific phospholipase C (PC-PLC) inhibitor with a K_i of 6.4 μM. D609 is an antioxidative protector and has antiviral and anti-inflammatory activity^[1][2][3]. IC50 & Target: Ki: 6.4 μM (PC-PLC) In Vitro: D609 (100 μM; for 2 h) significantly attenuats the proliferation of various cell lines^[2].
D609 (50, 100 and 200 μM; for 2 h) results in caspase-3 activation with 200 μM and causes no detectable cleavage with 50, 100 μM^[2].
D609 (100 μM; for 2 h) significantly inhibits BrdU incorporation in BV-2 microglia and causes accumulation of cells in G1 phase with decreased number of cells in the S phase^[2].
D609 (100 μM; for 2 h and cultured for an additional 2 h or 22 h without D609) increases ceramide levels, up-regulates p21 expression and causes a decreases in phospho-Rb^[2].
In Vivo: D609 (2.5, 10 mg/kg/day; ip; for 6 weeks) inhibits the progression of preexisting atherosclerotic lesions in apoE^-/- mice and changes the lesion composition into a more stable phenotype^[3].
D609 (50 mg/kg; ip; single dose) for 30 min before intratracheal administration of LPS (3 mg/kg) prevents the development of LPS-induced pulmonary hypertension in adult male Wistar rats^[4].